Comment
Author: Admin | 2025-04-28
2016; Gervasoni 2015; Ide 2018; Matsumoto 2010; Nukui 2013; Sasaki 2011; Tsuji 2017) although this may be reduced by a compensatory increase in non-renal elimination (Brier 2003; El-Assal 2014). Metabolites A and B accumulate in patients with renal insufficiency; the significance of this accumulation is not known. Use: Labeled IndicationsEnterococcal infections (vancomycin-resistant): Treatment of vancomycin-resistant Enterococcus faecium infections, including cases with concurrent bacteremia. Note: Not a preferred agent in resistant Enterococcus faecalis infections, which are usually susceptible to beta-lactams (O’Driscoll 2015).Pneumonia:Community-acquired: Treatment of community-acquired pneumonia (CAP) caused by Streptococcus pneumoniae, including cases with concurrent bacteremia, or Staphylococcus aureus (methicillin-susceptible isolates only). Note: Not a preferred agent for CAP; may be used as an alternative in multidrug-resistant S. pneumoniae and methicillin-resistant S. aureus (MRSA) pneumonia. For methicillin-susceptible S. aureus, the use of beta-lactams is preferred (IDSA/ATS [Mandell 2007]).Hospital-acquired or healthcare-associated: Treatment of hospital-acquired or healthcare-associated pneumonia caused by S. aureus (methicillin-susceptible and methicillin-resistant isolates) or S. pneumoniae. Note: For methicillin-susceptible S. aureus, the use of beta-lactams is preferred (IDSA/ATS [Kalil 2016]).Skin and skin structure infections:Complicated: Treatment of complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis, caused by S. aureus (methicillin-susceptible and methicillin-resistant isolates), Streptococcus pyogenes, or Streptococcus agalactiae.Uncomplicated: Treatment of uncomplicated skin and skin structure infections caused by S. aureus (methicillin-susceptible isolates) or S. pyogenes.Note: Generally reserved as alternative for skin and skin structure infections due to MRSA (IDSA [Liu 2011]; IDSA [Stevens 2014]).Limitations of use: Linezolid has not been studied in the treatment of decubitus ulcers. Linezolid is not indicated for treatment of gram-negative infections; if a concomitant gram-negative pathogen is documented or suspected, initiate specific therapy immediately. Use: Off LabelAnthrax, systemic infectionyesBased on the Centers for Disease Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults, linezolid is an
Add Comment